Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

MMRF’s Review Of Novel Therapy News From ASH

Home/MMRF’s Review Of Novel Therapy News From ASH

MMRF’s Review Of Novel Therapy News From ASH

Here is a copy of the MMRF’s review of novel therapy news from ASH last week:

Novel drugs
Data from two investigational trials of pomalidomide in relapsed or refractory myeloma patients after treatment with Revlimid or Revimid and bortezomib was presented at the meeting.
Results from an ongoing Phase II study showed promising overall response rates of carfilzomib as a single agent in patients with relapsed and/or refractory multiple myeloma.
Data from a separate study showed carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory myeloma patients.
Positive data was presented from a Phase I/II study of elotuzumab plus lenalidomide and low-dose dexamethasone in relapsed myeloma.
Updated safety, efficacy and survival data were presented on KRX-0401 in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma.
Novartis planned to present at the American Society of Hematology annual meeting efficacy data from two early-stage studies on LBH589, or panobinostat, in pre-treated patients with multiple myeloma. The company also planned to present early Phase I trial data of BHQ880 in combination with Zometa and an approved anti-myeloma therapy in relapsed or refractory myeloma patients who experienced a prior skeletal-related event.
A Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma showed the drug suppresses the pathway in tumor cells at well-tolerated doses.
Trial data showed IMGN901 achieved a prolonged benefit in relapsed and relapsed/refractory myeloma patients whose disease had progressed on multiple prior treatment regimens.

I have been covering, and will do my best to continue to cover, each and every development mentioned above in detail. I probably already have! Simply type in the drug or drug company name in the info bar at the top left of the page and related articles should magically appear! If they don’t, it may be because I used a name instead of a number or a number instead of a name. That’s OK. Just leave me a note in the comments or e-mail me at: Pat@HelpWithCancer.Org and I will get you the information.

Feel good and keep smiling! Pat